Answers are grounded in this paper and cite their sources.
To monitor the dynamics of the immune response against SARS-CoV-2, a test for the quantitative determination of IgG antibodies to the S protein of the SARS-CoV-2 coronavirus is used using chemiluminescent immunoassay (CLIA), which is standardized and widely implemented. There are no standardized methods for assessing and monitoring the cellular link of immunity against SARS-CoV-2, which is due to several reasons: the use of expensive equipment and reagents that are not included in the standard equipment of clinical diagnostic laboratories; lack of automated methods, high technological complexity of the study; underestimation of the role of T-cell immunity in providing long-term immune protection against SARS-CoV-2. Specific anti-SARS-CoV-2 T-cells circulate in the body for a longer time than the corresponding antibodies, so there is a need to monitor cellular immunity at the population level. Thus, reliable and scalable methods aimed at studying cellular immunity are needed. There are a number of tests that allow for fairly large-scale studies, such as ELISPOT (enzyme-linked immunosorbent assay), enzyme-linked immunosorbent assay (ELISA), and flow cytometry. Each method has its own advantages and disadvantages. There are active efforts to modernize, improve, and reduce the cost of various technologies and tests aimed at tracking the cellular link of immunity against SARS-CoV-2, with the goal of making them available for routine use.
No takes yet. Share an insight, caveat, or question.
Ivanova et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: